The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://safajyak093937.ambien-blog.com/45579223/retatrutide-vs-tirzepatide-a-comparative-analysis